Johnson & Johnson Recalls Motrin From Retailers

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Johnson & Johnson (NYSE: JNJ  ) has issued its latest recall of Motrin, this time from retailers over slow-working tablets and caplets, bringing the number of recalls for this drug alone to six in the past two years and calling attention to the manufacturing woes faced by the drugmaker.

J&J subsidiary McNeil's consumer divisionrecalled 12 million bottles of Motrin coated caplets and tablets from retailers distributed in the United States, Puerto Rico, the Bahamas, Fiji, Belize, St. Lucia, and Jamaica.

It is the latest in a series of recalls the New Brunswick, N.J., company has issued, ranging from over-the-counter medication to hip replacements from its subsidiary, DePuy Orthopaedics. Analysts estimate DePuy's hip implants alone could cost Johnson & Johnson as much as $1 billion in lawsuits. The metal-on-metal hip implants were found to shed metal particles into a patient's bloodstream over time.

In March, the frequency of recalls for its over-the-counter division prompted Johnson & Johnson to announce it would overhaul its McNeil consumer health-care division, particularly at its manufacturing plants in Las Piedras, Puerto Rico, and Fort Washington, Pa.

In another bit of bad news for the drugmaker, a U.S. District Court judge in New Jersey is allowing a securities fraud suit brought by investors to go forward. The lawsuit alleges Johnson & Johnson misled investors about quality control lapses at the McNeil plants that led to recalls.

The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1748451, ~/Articles/ArticleHandler.aspx, 10/20/2016 9:16:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 52 seconds ago Sponsored by:
DOW 18,162.35 -40.27 -0.22%
S&P 500 2,141.34 -2.95 -0.14%
NASD 5,241.83 -4.58 -0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/20/2016 4:02 PM
JNJ $114.87 Up +0.28 +0.24%
Johnson and Johnso… CAPS Rating: ****